Becton, Dickinson and Co. | BDX - Current Assets


Becton, Dickinson and Co. reported $8.01B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Abbott USD 25.51B 488M Mar/2026
Agilent USD 4.76B 148M Mar/2026
Align Technology USD 2.66B 7.62M Jun/2026
AngioDynamics USD 161.35M 4.69M Sep/2025
Avanos Medical USD 325M 30.4M Mar/2026
Baxter International USD 6.99B 142M Jun/2026
Becton, Dickinson and Co. USD 8.01B 1.18B Mar/2026
Bio-Rad Laboratories USD 2.94B 35.9M Mar/2026
Boston Scientific USD 7.97B 712M Jun/2026
Cooper Companies USD 2.3B 166M Mar/2026
Danaher USD 13.38B 554M Jun/2026
Dentsply International USD 1.85B 178M Mar/2026
Dexcom USD 4.09B 245.1M Jun/2026
Edwards Lifesciences USD 6.23B 510.2M Mar/2026
Globus Medical USD 2.2B 72.51M Mar/2026
Insulet USD 1.71B 204.5M Mar/2026
Integra LifeSciences USD 1.19B 19.46M Jun/2026
Intuitive Surgical USD 12.33B 807.5M Jun/2026
J&J USD 59.77B 601M Jun/2026
Medtronic USD 24.07B 75M Dec/2025
Solventum Corp USD 3.58B 276M Mar/2026
Stryker USD 14.42B 1.08B Jun/2026
Tandem Diabetes Care USD 887.1M 268.96M Mar/2026
Teleflex USD 1.86B 78.67M Mar/2026
Terumo JPY 861.04B 45.48B Mar/2026
Thermo Fisher Scientific USD 23.36B 1.05B Jun/2026
Zimmer Biomet Holdings USD 4.96B 157.4M Mar/2026